Form 4: Puma Biotechnology Chief Commercial Officer Sells Shares Under 10b5-1 Plan

Puma Biotechnology's Chief Commercial Officer, Jeffrey Jerome Ludwig, sold 9,437 shares of common stock at an average price of $3.1517 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Jeffrey Jerome Ludwig, Chief Commercial Officer of Puma Biotechnology, sold 9,437 shares of common stock on January 2, 2025.
• The shares were sold at a weighted average price of $3.1517 per share.
• The sale was executed under a pre-existing 10b5-1 trading plan adopted on December 14, 2020.
• The price range for the transactions was between $3.11 and $3.2101 per share.
• Following the transaction, Mr. Ludwig directly owns 108,951 shares of Puma Biotechnology common stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing for an insider stock sale under a pre-arranged plan, which is neither positive nor negative for the company's outlook.

Industry Context

This is a routine filing related to insider trading activity and is common for executives who have pre-arranged trading plans. It does not indicate any specific change in the company's outlook or performance.

Comparison to Industry Standards

• Sales by executives under 10b5-1 plans are a common practice across publicly traded companies.
• The reported transaction is consistent with standard insider trading reporting requirements.
• The volume of shares sold is relatively small compared to the total outstanding shares of Puma Biotechnology.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on investor sentiment, but is unlikely to significantly affect the share price due to the pre-planned nature of the transaction.

Key Dates

Keywords

Puma Biotechnology, Jeffrey Jerome Ludwig, insider trading, stock sale, 10b5-1 plan, PBYI, Chief Commercial Officer